Results of a study conducted by researchers at the National Institutes of Health Clinical Center show that St. John's wort, an herbal product used to treat depression, could significantly undermine the effectiveness the antiviral drug indinavir, which is often prescribed to treat HIV infection.
Results of a study conducted by researchers at the National Institutes of Health Clinical Center show that St. John's wort, an herbal product used to treat depression, could significantly undermine the effectiveness the antiviral drug indinavir, which is often prescribed to treat HIV infection.
"When St. John's wort and the protease inhibitor indinavir are taken together, the levels of indinavir in the blood drop dramatically," explained the study's principal investigator, clinical pharmacokineticist Dr. Stephen Piscitelli of the NIH Clinical Center's Pharmacy Department. "When the body eliminates the antiviral drug too quickly, there can be a loss of therapeutic benefit."
AIDS research clinician Dr. Judith Falloon of the Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, collaborated on the study, which is featured in The Lancet (vol. 355, no. 9203).
"St. John's wort's effects on indinavir concentrations are large enough to be clinically significant," Falloon said. "Patients and healthcare professionals need to be aware of this interaction. Most people taking medications to treat HIV infection should avoid using St. John's wort."
The NIH Clinical Center study, conducted among eight healthy volunteers, first measured the amount in the body of the drug indinavir when taken alone. Next, study participants were given only St. John's wort for two weeks. Finally, indinavir and St. John's wort were given together.
"The results were dramatically conclusive," Piscitelli said. "All the participants showed a marked drop in blood levels of indinavir after taking St. John's wort. The drop ranged from 49% to 99%."
Added Piscitelli, "Many people think that herbal products like St. John's wort are safe, but there can be dangerous interactions when taken with other medications prescribed to treat medical conditions. This study demonstrates how dangerous that interaction can be and how important it is for patients to keep their physician and pharmacist informed about any use of herbal products." PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.